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Abstract
Background: [11C]Befloxatone measures the density of the enzyme monoamine oxidase A (MAO-A) in the brain.
MAO-A is responsible for the degradation of different neurotransmitters and is implicated in several neurologic and
psychiatric illnesses. This study sought to estimate the distribution volume (VT) values of [
11C]befloxatone in humans
using an arterial input function.
Methods: Seven healthy volunteers were imaged with positron emission tomography (PET) after [11C]befloxatone
injection. Kinetic analysis was performed using an arterial input function in association with compartmental
modeling and with the Logan plot, multilinear analysis (MA1), and standard spectral analysis (SA) at both the
regional and voxel level. Arterialized venous samples were drawn as an alternative and less invasive input function.
Results: An unconstrained two-compartment model reliably quantified VT values in large brain regions. A
constrained model did not significantly improve VT identifiability. Similar VT results were obtained using SA;
however, the Logan plot and MA1 slightly underestimated VT values (about −10%). At the voxel level, SA showed
a very small bias (+2%) compared to compartmental modeling, Logan severely underestimated VT values, and
voxel-wise images obtained with MA1 were too noisy to be reliably quantified. Arterialized venous blood samples
did not provide a satisfactory alternative input function as the Logan-VT regional values were not comparable to
those obtained with arterial sampling in all subjects.
Conclusions: Binding of [11C]befloxatone to MAO-A can be quantified using an arterial input function and a
two-compartment model or, in parametric images, with SA.
Keywords: [11C]Befloxatone; Monoamine oxidase A; PET; Spectral analysis
Background
Monoamine oxidase (MAO) is a mitochondrial enzyme re-
sponsible for the degradation of several neurotransmitters,
such as dopamine, serotonin, and noradrenaline. Two
MAO isoforms - products of different genes - have been
identified in mammals: enzyme monoamine oxidase A
(MAO-A), which is primarily found in cathecolaminergic
neurons, and MAO-B, which is mainly present in glial cells
and serotonergic neurons [1]. MAO-A is widespread in the
human brain; the highest concentrations are found in the
thalamus and the occipital cortex, intermediate values are
found in the basal ganglia, and lower concentrations are
seen in the frontal cortex and cerebellum [1,2]. MAO-A
dysfunction has been implicated in several neurologic ill-
nesses such as Parkinson's disease, Alzheimer's disease,
and Huntington's disease, as well as in psychiatric diseases
such as major depressive disorder [3]. Notably, several
studies have linked MAO-A enzyme activity and gene
expression to tobacco addiction [2,4-7].
With some exceptions [6], studies on MAO-A activity
have been hindered by the lack of suitable ligands for
this enzyme. For instance, the metabolism rate of [11C]
harmine in the plasma is very high, thus making a reli-
able quantification of the input function challenging [8],
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and [11C]brofaromine has very little displaceable bind-
ing [9].
Befloxatone is a potent, selective, and reversible inhibi-
tor of brain MAO-A activity [10]. It can be radiolabeled
with 11C using [11C]phosgene as the reagent [11]. [11C]
Befloxatone has a highly specific binding to MAO-A, as
shown by extensive in vitro [10] and in vivo studies in
primates [12]. In particular, nonsaturable uptake, ob-
tained after a pretreatment with a high dose of unlabeled
befloxatone, is very low and represents only 3% of the
total uptake [12]. [11C]Befloxatone has good imaging
characteristics and has been used in positron emission
tomography (PET) studies to quantify in vivo MAO-A in
rats [13], nonhuman primates [12,14], and humans. In
humans, it has been used to compare MAO-A binding
potential in smokers and nonsmokers [7]; however, a
rigorous kinetic modeling study in humans has never
been performed. This paper sought to (1) quantify the
uptake of [11C]befloxatone in the human brain, both at
the regional and voxel level, using an arterial input
function; and (2) explore the possibility of replacing the
arterial input function with a less invasive approach
based on sampling of arterialized venous blood.
Methods
Subjects
Seven healthy, nonsmoker, male volunteers (72 ± 9.5 kg,
age 26 ± 4.5 years) from a previous clinical protocol were
included in this study [7]. All subjects were free of current
medical or psychiatric illnesses and had no history of
drug or alcohol abuse. Subjects were instructed to avoid
monoamine-rich food 3 days before and alcohol consump-
tion 1 week before imaging. Vital signs (blood pressure,
heart rate) were recorded before [11C]befloxatone injec-
tion and at the end of the scan. The study was approved
by the regional ethics committee for biomedical research
at the Bicêtre Hospital. Each subject gave a written infor-
med consent.
Brain image acquisition
PET scans were performed on an ECAT EXACT HR+
scanner (Siemens Medical Solutions, Knoxville, TN, USA).
One transmission scan was acquired before intravenous
bolus injection of [11C]befloxatone (290 ± 24.4 MBq). The
specific activity was 35.2 ± 14.9 GBq/μmol, which is within
the range of the values usually obtained from the synthesis
of [11C]befloxatone [11] and sufficient to rule out any
mass effect. Even when considering a conservative Bmax
value of 99 pmol/mL (as found in vitro in the human
cerebellum [14]), the Bmax occupancy is well below 1% in
each subject. Dynamic three-dimensional images were
acquired over 60 min in 29 frames, whose duration ranged
from 10 s to 5 min. Images were reconstructed with
filtered back projection.
Each subject also underwent brain T1-weighed three-
dimensional magnetic resonance imaging (MRI) using a
1.5 T Signa scanner (GE Healthcare, Milwaukee, WI,
USA). MRI images were acquired with a voxel size of
0.938 × 0.938 × 1.3 mm3 and a thickness of 1.3 mm in
axial slices.
Measurement of [11C]befloxatone in arterial and venous
plasma
Arterial blood samples were drawn from the radial artery
of each subject in 10-s intervals until 2 min, followed by
samples at 3, 4, and 5 min and then every 5 min until
the end of the scan at 60 min. About 27 samples were
drawn for each subject. For each blood sample, the
decay-corrected concentration of [11C]befloxatone was
measured in whole blood and plasma. Plasma was
obtained by centrifugation. Plasma-free fraction was not
measured. Venous blood samples were simultaneously
drawn from the cubital vein of the opposite arm, using
the same number of samples and time schedule as the
arterial ones. As for arterial blood, plasma was separated
from total venous blood. Arterialization of venous blood
was achieved by heating the arm with hot water bags,
starting 30 min before ligand injection until the end of
the scan. The bags were replaced every 20 to 30 min.
Four or five times during each scan, blood gases
(pO2 and pCO2) were measured in five subjects.
The whole plasma time-activity curves were taken as
input functions because in a previous series of (yet
unpublished) four human scans from our laboratory,
chromatograms obtained with high-performance liquid
chromatography (HPLC) did not show any detectable
radiometabolites in the plasma, even at late time points.
The technique we used to measure the amount of
unchanged radiotracer in the plasma was similar to that
described in [14]. Specifically, after deproteinization with
acetonitrile, the samples were centrifuged and the super-
natant was injected directly into the HPLC column. A
reverse-phase μBondapak C18 column (300 × 7.8 mm,
10 μm; Waters, Milford, MA, USA) was eluted applying
a gradient from 20% acetonitrile in 0.01 M phosphoric
acid up to 80% in 5.5 min, to 90% at 7.5 min, and
returning to 20% at 7.6 min with a total run length of
10 min. The flow rate of the eluent was maintained at
6 mL/min. Befloxatone was eluted with a retention time
of 6 min. Data acquisition and analysis were carried out
using Winflow software (version 1.21, JMBS Developments,
Grenoble, France).
Brain image analysis
The summed PET image, obtained by averaging all
frames, was first coregistered to the individual MRI using
SPM5 (Wellcome Department of Cognitive Neurology,
London, UK). MRI and PET images were then normalized
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to the Montreal Neurologic Institute (MNI) space using
the transformation parameters from the MRI images. A
template of regions of interest (ROIs) [15] was used to
extract brain time-activity curves for the following 13
regions: anterior and posterior cingulate cortices, caudate,
putamen, thalamus, pons, cerebellum, hippocampus, para-
hippocampus, and the prefrontal, parietal, temporal, and
occipital cortices. Each region was obtained from the
weighted average of the left and right region. Image
analysis and kinetic modeling were performed with Pmod
3.1 (Pmod Technologies, Zurich, Switzerland).
Calculation of distribution volume
Because [11C]befloxatone is a reversible MAO-A inhibitor
[11], kinetic analysis was performed using one- (1TCM)
and two-tissue compartment (2TCM) model to calculate
the total distribution volume (VT), which equals the ratio
at equilibrium of the concentration of radioligand in the
brain to that in the plasma [16]. VT is the sum of the bind-
ing in the specific compartment (VS) and in the nondis-
placeable compartment (VND). In theory, VT may change
not only as a function of VS but also of VND. However, in
kinetic modeling studies,VND is commonly assumed to be
constant across different brain regions and across different
subjects of the same species. Thus, variations of VT are
considered to reflect variations of VS values. For [
11C]
befloxatone in particular, in vivo studies in primates
showed that, after pharmacological blockade, the residual
radioactive concentrations were very low and identical in
all brain structures [11]. The 2TCM analysis was per-
formed in two ways, (1) without constraining the rate con-
stants and (2) fixing the ratio K1/k2 to the value obtained
in the whole brain, to improve the identifiability of param-
eters. The individual rate constants were estimated with
the weighted least square method and with the Marquardt
optimizer. Brain activity was corrected for its vascular
component using the measured whole blood concen-
trations, assuming that the cerebral blood volume is 5% of
the total brain volume [17]. The delay of radiotracer
arrival between the radial artery and the brain was
corrected by fitting the whole brain. The plasma input
function was modeled using a linear interpolation of the
[11C]befloxatone concentrations before the peak and a
tri-exponential fit of concentrations after the peak.
Kinetic modeling was also performed at the regional
level using the graphical Logan plot (Loganvoi), Ichise's
multilinear analysis (MA1voi), and a standard spectral
analysis (SAvoi).
Logan plot
The Logan plot is a model-independent graphical method
for reversible tracers [18]. It performs a linearization of
the data so that, after a certain time (t > t*), the slope can
be related to the VT, according to
Z t
0
CT τð Þdτ
CT tð Þ
¼ VT
Z t
0
CP τð Þdτ
CT tð Þ
þ c ð1Þ
where CT represents the tissue concentration and Cp the
plasma activity.
The Logan plot is a computationally quick and robust
technique. It may, however, underestimate VT, especially
in the case of small and noisy regions [19].
Multilinear analysis
The multilinear analysis (MA1) is a modification of the
Logan plot developed to remove noisy measurements
(CT) from the independent variables [20], according to
the following equation:
CT tð Þ ¼ −
V
b
Z t
0
Cp τð Þdτ þ
1
b
Z t
0
CT τð Þdτ ð2Þ
where V is the total distribution volume and b is the inter-
cept of the Logan plot that becomes constant at t > t*.
This approach has been shown to minimize VT estimation
bias in the case of noisy measurements [20].
Spectral analysis
This technique is based on a time-invariant single input/
single output model used to identify tissue kinetic
components [21]. As with the Logan plot, SA does not
require prior knowledge of the number of compartments
in the system. The tissue concentration, CT(t), is
obtained by convolving the plasma time-activity curve,
CP(t), with the sum of M+ 1 exponentials, as follows:
CT tð Þ ¼
XM
j¼0
Cp tð Þ⊗ αje
−βjt ¼
XM
j¼0
αj
Z t
0
Cp τð Þe−βj t−τð Þdτ
ð3Þ
where αj and βj are assumed to be real-valued and
nonnegative.
VT was calculated from the estimated spectrum as
VT ¼
XM
j¼1
αj
βj
ð4Þ
In the present study, the βj grid was defined with a
maximum value of 100 and a logarithmic distribution of
βj, j = 1, 2… M, using a spectral range from 0.01 to 1. SA
was performed using the SAKE software [22].
Finally, we sought to determine whether VT values
could be obtained from voxel-wise analysis. We created
parametric images using the Logan plot (Loganvoxel),
multilinear analysis (MA1voxel), and standard spectral
analysis (SAvoxel). For Loganvoxel and MA1voxel, the PET
frames used for regression were selected on the basis of
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the start time obtained from the time-activity curve of
the whole brain. For all parametric images, regional
values were obtained by averaging the voxel values
within each region.
Statistical analysis
Goodness of fit by nonlinear least squares analysis was
evaluated using the Akaike information criterion (AIC)
and model selection criterion (MSC). The most appro-
priate model is that with the smallest AIC and the
largest MSC score. Goodness of fit by the one- and two-
compartment models was compared with F statistics
[23]. A value of P < 0.05 was considered significant. The
identifiability of kinetic variables was expressed as a per-
centage of the rate constant and calculated as standard
error obtained from the diagonal of the covariance
matrix [24]. Standard error for VT was calculated from the
covariance matrix using the generalized form of error
propagation equation [25], where correlations among
parameters are taken into account. Smaller values indicate
better identifiability.
For each subject, regional VT values obtained with
2TCM at the regional level were considered as the gold
standard. Comparisons to the VT calculated with Loganvoi,
MA1voi, SAvoi, Loganvoxel, MA1voxel, and SAvoxel were per-
formed with a repeated measures analysis of variance
(ANOVA) for VT values in the various regions. Statistical
analyses were performed with SPSS (version 17 for
Windows; SPSS Inc., Chicago, IL, USA).
Results
Measurement of [11C]befloxatone in arterial and venous
plasma
[11C]Befloxatone concentrations in arterial plasma
peaked about 30 s after injection at 21 ± 7.1 standard up-
take value (SUV) and then rapidly decreased. Both the
plasma and whole blood arterial curves were well fitted
by a tri-exponential function. Venous concentrations
peaked about 50 s after injection with an SUV of 6.7 ± 2.6.
Pairs of arterial and venous samples were sometimes
drawn with a few seconds of delay in either direction.
Therefore, in order to compare arteriovenous concentra-
tions of the radioligand, we fitted the plasma time-
activity curves with a tri-exponential function and inter-
polated the values at the same grid of standard times. The
average pO2 measured in venous blood was 77% ± 8% of
the pO2 measured in the arterial blood. The average pCO2
in the vein was 101% ± 1% compared to the arterial value.
A stable arteriovenous equilibrium of [11C]befloxatone
concentrations was found only a few minutes after in-
jection (Figure 1). Average arteriovenous differences were
already at about 5% or less within 2.5 min after injection
and remained unchanged until the end of the scan
(Figure 2). After the peak, in each individual subject the
arteriovenous difference was almost always less than 10%
at each time point. One subject, however, had differences
between 10% and 20% at each time point from 40 min
after injection to the end of the scan. A good correlation
was found between arterial and venous concentrations at
each time point from 3 to 60 min (n = 13 pairs). R2 ranged
from 0.64 at 3 min to 0.99 at 30 min.
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Figure 1 Plasma time-activity curve of [11C]befloxatone
concentrations in arterial and venous blood for a
representative subject. The main frame shows the first 10 min; the
inset magnifies the remaining part of the input function. Red curve,
arterial blood; blue curve, venous blood. The venous peak was
predictably much lower than the arterial one, but [11C]befloxatone
concentrations were remarkably similar immediately after the peak
until the end of the scan. Although compartmental modeling
cannot be used with a venous input due to the different shapes of
the early part of the curves, the Logan graphical analysis only
depends on the total area under the curve. For this subject, the VT
error using only the venous input was 7.2% compared to the
reference VT values obtained with the arterial input.
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Figure 2 Arteriovenous difference of radioligand concentrations
(mean ± SD) across the different subjects. Equilibrium was
reached within 3 min of injection and remained stable until the end
of the scan.
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Brain radioactivity and kinetic analysis
Radioactivity showed a rapid uptake in the brain,
progressively increased during the first 25 min (mean
peak value, 1.5 to 2 SUV), and then slowly decreased
(Figure 3). These time-activity curves were very similar
to those described for [11C]befloxatone in nonhuman
primates [12].
Radioactivity uptake was widespread and distributed
fairly homogeneously across the brain (Figure 4). Consist-
ent with the known distribution of MAO-A [2], a lower
uptake was noted in the cerebellum of all subjects (the
cerebellar area under the curve was about 35% lower than
the mean value of the whole brain). However, because low
amounts of MAO-A are expressed in the cerebellum [26],
analysis with a reference region was not used.
The brain kinetic analysis had two major results: (1)
[11C]befloxatone binding in the brain was better described
by a two-tissue compartment model but the 2TCM with a
constraint of K1/k2 did not provide a better goodness of fit
for VT, and (2) both at the regional and voxel level, SA
provided better VT estimates than Logan and MA1.
As regards the first finding, unconstrained one- and
two-compartment fitting converged in all regions and in
all scans. Fitting was visually quite similar using either
model; however, the two-tissue compartment model
showed lower mean AIC (−22.3) and higher mean MSC
(4.2) scores than the one-compartment model (AIC = 1.1,
MSC = 3.4). The superiority of 2TCM was confirmed by
F statistics. In addition, SA showed at least two equilibrat-
ing components in all regions for all subjects. The average
identifiability across brain regions for two-compartment
fitting was 4.7%. The average VT value across all brain
regions was 14.3 ± 3.0 mL/cm3. The highest binding was
found in the thalamus (average VT of 19.3 ± 1.4 mL/cm
3),
and the lowest in the cerebellum (6.7 ± 0.9 mL/cm3)
(Table 1). The constrained two-compartment model fit-
ting converged in all regions and in all scans but provided
a similar goodness of fit (AIC = −20.8 and MSC = 4.1) as
the unconstrained model. The average identifiability
across brain regions was 4.4% (versus 4.7% for the uncon-
strained fitting).
As regards the second point, Loganvoi and MA1voi
underestimated VT values by about 10% (Figure 5A), and
these differences were statistically significant (p < 0.05;
factorial repeated measures ANOVA using Bonferroni
adjustment, F1.33,8.01 = 57.93). In contrast, VT values
obtained with SAvoi had an average bias of only +1%
(range −7% to +6%) and were not statistically different
from the reference values obtained with 2TCM (p > 0.05).
Loganvoi, MA1voi, and SAvoi correlated well with the refer-
ence VT values obtained with the 2TCM: R
2 was >0.90 for
all subjects, except for one subject in whom R2 for SAvoi
was 0.73. Loganvoxel severely underestimated VT, with an
average difference of −40% (p < 0.05) (Figure 5B). More-
over, linear regression analysis showed that Loganvoxel was
significantly correlated to 2TCM VT values in only four of
seven subjects. The parametric images obtained with
MA1 (MA1voxel) contained many noisy voxels that pre-
vented reliable quantification. These noisy voxels were
located predominantly, but not exclusively, in areas where
blood flow (K1) is low, such as the white matter. Attempts
to eliminate these noisy voxels by adjusting K1 values were
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Figure 3 Representative brain time-activity curves in one
subject. Three regions are shown: putamen (empty circle), parietal
cortex (filled circle), and cerebellum (empty square). Lines represent
fitting with unconstrained 2TCM.
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B
Figure 4 Brain images. MRI (A), summed PET (B), and VT
parametric images in a representative subject. The parametric
images were calculated with the Logan plot (C) and spectral analysis
(D) and are shown with the same color scale. Parametric images
obtained with MA1 (not shown) were too noisy to be quantified.
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not successful. Therefore, MA1voxel was not considered
for further analysis. Compared to 2TCM, VT values
obtained with SAvoxel showed a mean bias of only +2%
(range, −10% to +7%) and were not statistically different
(p > 0.05) from the reference values. Predictably, SAvoxel
values were higher than Loganvoi, Loganvoxel, and MA1voi
(p < 0.05). Finally, SAvoxel significantly correlated with
2TCM in all subjects: R2 for brain regions ranged from
0.81 to 0.95, except in one subject who had an R2 of 0.60.
Use of a venous input function
Logan-VT results obtained with a full venous input func-
tion were consistent with Logan-VT results obtained
with an arterial plasma input function in six subjects
(with an error <10% compared to the reference values
obtained with the arterial input function). However, in
one subject, Logan-VT was overestimated by 27%.
Discussion
This study sought to quantify [11C]befloxatone binding
in human brain using arterial blood samples and PET
imaging. We also assessed whether arterial cannulation
could be avoided by replacing arterial samples with
arterialized venous samples.
We found that [11C]befloxatone binding is better
quantified using a two-tissue compartment model or SA.
Venous samples cannot, however, be a reliable substitute
for arterial samples.
Despite a slow washout of the radioligand from the
brain, VT values were well identified with an uncon-
strained two-tissue compartment model (mean standard
error, 4.7%). A constrained 2TCM did not provide a clear
advantage for VT estimation over the unconstrained
model. VT values were higher in the basal ganglia and the
cortical structures (about 12 to 19 mL/cm3) and lower in
the cerebellum (about 7 mL/cm3). These values were
slightly lower than the VT values previously found in
baboons, where the VT was 19 to 23 mL/cm
3 for high-
uptake regions and 10 to 11 mL/cm3 for the cerebellum
[12]. Notably, in a previous study in baboons, we used a
three-compartment model, corresponding to the free
ligand in the tissue, the ligand specifically bound to the
receptors and the nonspecific binding [14]. However, the
concentration of the nonspecific binding was very low in
all regions, and the equilibrium between the free and
the nonspecific ligand was reached relatively quickly,
compared with the equilibrium between the other
compartments [14]. Therefore, the nonspecific and the
free compartments of [11C]befloxatone can be lumped
together in a two-tissue model.
Compared with 2TCM, both the Logan plot (Loganvoi)
and the multilinear analysis (MA1voi) significantly under-
estimated VT values in large brain regions (about −10%).
In contrast, the average bias of VT values obtained with
standard SAvoi was only 1%.
Owing to the sensitivity of the Logan plot to noise,
especially at the voxel level, Loganvoxel severely underes-
timated VT values (−40% on average) and did not signifi-
cantly correlate with 2TCM VT in three out of the seven
subjects. Multilinear analysis has been shown to be more
robust to noise-induced bias [20]. However, parametric
images (MA1voxel) contained numerous noisy voxels and
were therefore not amenable to quantification. SA was
the only technique capable of providing good results at
the voxel level. Indeed, SAvoxel showed only a small, non-
significant bias (+2%) compared to VT values obtained
with 2TCM and correlated well with 2TCM for all sub-
jects. As this study shows, when the most commonly used
Table 1 Distribution volume calculated from compartmental modeling, Logan plot, MA1, and SA using regions or
individual voxels
Region VT (mL/cm
3)
Region Voxel
Unconstrained two-tissue compartment model Logan MA1 SA Logan SA
Frontal cortex 13.3 ± 0.84 (2.7) 12.5 ± 0.79 11.8 ± 0.71 13.6 ± 1.21 8.66 ± 2.14 13.7 ± 0.90
Temporal cortex 15.1 ± 1.04 (2.6) 14.1 ± 0.90 13.5 ± 0.83 15.3 ± 0.85 9.69 ± 2.64 15.4 ± 0.97
Hippocampus 16.2 ± 1.11 (6.9) 14.8 ± 1.09 13.8 ± 0.75 15.2 ± 1.74 6.36 ± 1.87 14.4 ± 1.79
Parietal cortex 13.0 ± 0.61 (2.8) 12.3 ± 0.53 11.6 ± 0.40 13.3 ± 0.94 8.59 ± 2.20 13.5 ± 1.10
Occipital cortex 15.4 ± 1.08 (2.8) 14.4 ± 0.99 13.6 ± 0.83 15.5 ± 1.20 9.87 ± 2.19 15.7 ± 1.13
Anterior cingulum 16.2 ± 1.56 (4.6) 15.2 ± 1.43 14.7 ± 1.20 16.9 ± 2.02 9.94 ± 2.56 16.2 ± 0.90
Caudate 12.5 ± 1.20 (7.7) 11.4 ± 1.00 11.0 ± 0.73 12.4 ± 1.21 7.17 ± 1.94 13.0 ± 1.36
Putamen 14.8 ± 0.67 (3.8) 13.9 ± 0.77 13.3 ± 0.70 15.2 ± 0.80 10.3 ± 3.00 16.5 ± 0.99
Thalamus 19.3 ± 1.43 (5.6) 17.7 ± 1.69 16.5 ± 1.18 19.5 ± 2.33 10.1 ± 3.11 19.0 ± 2.32
Cerebellum 6.73 ± 0.91 (2.5) 6.42 ± 0.82 6.18 ± 0.75 6.83 ± 0.95 5.19 ± 1.98 7.58 ± 0.86
Values are presented as mean ± SD from seven human subjects. For each brain region, standard errors are listed in parentheses and are expressed as the
percentage of the variable itself.
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graphical approaches fail to provide parametric images of
good quality, SA can be a valid alternative. The use of SA
has long been hampered by the complexity of its im-
plementation. However, new user-friendly software, such
as SAKE or Pmod 3.4, may encourage its use for clinical
protocols where statistical parametric mapping analyses
are performed.
Autoradiography and immunohistochemistry data have
demonstrated that MAO-A is widespread in the brain
[27,28]. Moreover, studies of nonhuman primates found
that [11C]befloxatone binding was displaceable in all brain
regions [12]. These data suggest that a reference region
may not exist to quantify [11C]befloxatone binding. With-
out a reference region, quantification can only be achieved
by using an arterial plasma input function, which is an in-
vasive procedure. In addition, measuring the arterial input
function usually requires labor-intensive HPLC analyses.
However, one of the favorable characteristics of [11C]
befloxatone is that no radiometabolites are detected in the
plasma. In consequence, [11C]befloxatone input function
can be easily achieved using only plasma isolation without
HPLC analyses. Notably, our previous analysis in baboons
showed that [11C]befloxatone radiometabolites constituted
about 20% of plasma radioactivity at 30 min after
injection [14]. This discrepancy was due to interspe-
cies differences and possibly linked to the faster metabol-
ism of baboons.
To avoid arterial samples altogether, we sought to
validate the use of an input function composed of
arterialized venous samples. Indeed, arterialized venous
samples are routinely used in several institutions as a
replacement for arterial samples. A stable arteriovenous
equilibrium began from about 3 min after injection;
therefore, the early portions of the arterial and venous
input functions (i.e., the peaks) were dissimilar. This is a
common finding with most tracers and molecules and is
linked to the diffusion of the radiotracer in its volume of
distribution [29,30]. A different peak shape would pre-
vent the use of a venous full input in association with
compartmental modeling or SA. In contrast, the Logan
plot does not require that the shape of the peak be per-
fectly estimated because it relies on the total area under
the curve of the input function. Indeed, kinetic modeling
performed using a venous input function yielded Logan-
VT values which were consistent with those obtained
from arterial sampling: six out of seven subjects had
Logan-VT estimation errors smaller than 10%. There
was, however, one major outlier with an error of 27%,
and this suggests that arterialized samples might not be
a reliable alternative to the full arterial input function
for [11C]befloxatone imaging. Notably, this subject was
the only one to have a significant deviation from arterio-
venous equilibrium at a late time. However, the degree
of arterialization of the venous blood for this subject
(vein/artery ratio of 0.74 for pO2 and 1.03 for pCO2) was
similar to that of the others (0.77 ± 0.08 and 1.01 ± 0.01
for pO2 and pCO2, respectively). It is possible that a
higher degree of arterialization could have been achieved
using a different warming technique [31]. It should,
however, be noted that, even with optimal conditions,
arterialization of venous blood is difficult to achieve and
is plagued by intersubject variability [32]. Therefore,
unless a better equilibrium can be achieved with a differ-
ent technique, an arterial input function will be neces-
sary for the quantification of [11C]befloxatone binding.
Finally, it should be noted that despite having several
good imaging characteristics (high specific binding, low
metabolism in plasma), [11C]befloxatone has one impor-
tant drawback, i.e., a slow washout from the brain.
Although VT values were well identified, it would never-
theless be preferable to have a radioligand with a faster
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Figure 5 Regression analyses for VT results obtained from the
13 brain regions of a 23-year-old subject. (A) Spectral analysis
(filled square) provided good results with a very small bias (+1.4%).
Logan (empty circle) and MA1 (filled circle) slightly underestimated
VT values (−7.4% and −9.7%, respectively, for this subject). At the
voxel level (B), only SA provided results with a small bias and good
correlation with 2TCM (0.932x + 1.793, R2 = 0.92, p < 0.0001). In
contrast, Loganvoxel underestimated VT values by about 47%
(0.324x + 2.61, R2 = 0.32, p = 0.047).
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washout, even if there was a higher rate of metabolism
in the plasma (provided that radiometabolites do not
enter into the brain).
Conclusions
Binding of [11C]befloxatone to MAO-A can be quantified
using an arterial input function and a two-compartment
model or, in parametric images, with spectral analysis.
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